Bioventus (BVS) News Today $7.74 -0.18 (-2.27%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$7.74 +0.00 (+0.06%) As of 04/15/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Bioventus Inc. (NYSE:BVS) Shares Bought by Franklin Resources Inc.Franklin Resources Inc. increased its holdings in Bioventus Inc. (NYSE:BVS - Free Report) by 56.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 126,140 shares of the company's stock after buying an additional 45,728 shares during the period. Franklin ResoApril 16 at 3:36 AM | marketbeat.comBioventus Inc. (NYSE:BVS) Shares Acquired by Vanguard Group Inc.Vanguard Group Inc. boosted its stake in Bioventus Inc. (NYSE:BVS - Free Report) by 18.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,462,081 shares of the company's stock after acquiringApril 16 at 3:19 AM | marketbeat.comTrexquant Investment LP Has $467,000 Stock Holdings in Bioventus Inc. (NYSE:BVS)Trexquant Investment LP reduced its position in Bioventus Inc. (NYSE:BVS - Free Report) by 56.8% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 44,471 shares of the company's stock after selling 58,493 shares during the period. Trexquant Investment LP owned aboApril 15 at 4:20 AM | marketbeat.comPrudential Financial Inc. Has $927,000 Stock Position in Bioventus Inc. (NYSE:BVS)Prudential Financial Inc. grew its stake in Bioventus Inc. (NYSE:BVS - Free Report) by 650.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 88,260 shares of the company's stock after purchasing an additionaApril 9, 2025 | marketbeat.comAmerican Century Companies Inc. Buys 246,645 Shares of Bioventus Inc. (NYSE:BVS)American Century Companies Inc. raised its holdings in Bioventus Inc. (NYSE:BVS - Free Report) by 38.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 884,673 shares of the company's stock after buying an additional 246,April 4, 2025 | marketbeat.com70,500 Shares in Bioventus Inc. (NYSE:BVS) Acquired by Swiss National BankSwiss National Bank bought a new position in Bioventus Inc. (NYSE:BVS - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 70,500 shares of the company's stock, valued at approximately $740,000. Swiss National Bank oMarch 30, 2025 | marketbeat.comInsider Selling: Bioventus Inc. (NYSE:BVS) CFO Sells 5,479 Shares of StockBioventus Inc. (NYSE:BVS - Get Free Report) CFO Mark Leonard Singleton sold 5,479 shares of the company's stock in a transaction on Monday, March 24th. The stock was sold at an average price of $9.79, for a total value of $53,639.41. Following the sale, the chief financial officer now owns 131,963 shares of the company's stock, valued at $1,291,917.77. This trade represents a 3.99 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.March 26, 2025 | marketbeat.comMark Leonard Singleton Sells 5,479 Shares of Bioventus Inc. (NYSE:BVS) StockMarch 26, 2025 | insidertrades.comCharles Schwab Investment Management Inc. Grows Position in Bioventus Inc. (NYSE:BVS)Charles Schwab Investment Management Inc. grew its holdings in Bioventus Inc. (NYSE:BVS - Free Report) by 11.6% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 435,344 shares of the company's stock after buying an additionMarch 26, 2025 | marketbeat.comSheets Smith Investment Management Buys Shares of 142,723 Bioventus Inc. (NYSE:BVS)Sheets Smith Investment Management bought a new stake in shares of Bioventus Inc. (NYSE:BVS - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 142,723 shares of the company's stock, valued at approximately $1,499,000. Bioventus accountsMarch 25, 2025 | marketbeat.comSummit Global Investments Makes New Investment in Bioventus Inc. (NYSE:BVS)Summit Global Investments acquired a new stake in Bioventus Inc. (NYSE:BVS - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 52,675 shares of the company's stock, valued at approximately $553,000. Summit Global InvestmeMarch 25, 2025 | marketbeat.comBioventus Inc. (NYSE:BVS) Shares Bought by Bank of New York Mellon CorpBank of New York Mellon Corp boosted its stake in shares of Bioventus Inc. (NYSE:BVS - Free Report) by 37.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 125,055 shares of the company's stock after acquiring an additionalMarch 24, 2025 | marketbeat.comBioventus Inc. (NYSE:BVS) Position Increased by Royce & Associates LPRoyce & Associates LP boosted its stake in shares of Bioventus Inc. (NYSE:BVS - Free Report) by 5.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 732,236 shares of the company's stock after buying an additionaMarch 19, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Sells 62,577 Shares of Bioventus Inc. (NYSE:BVS)Connor Clark & Lunn Investment Management Ltd. lessened its holdings in shares of Bioventus Inc. (NYSE:BVS - Free Report) by 24.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 196,179 shares of the company's stock after sellingMarch 19, 2025 | marketbeat.comCanaccord Genuity Group Reiterates Buy Rating for Bioventus (NYSE:BVS)Canaccord Genuity Group reaffirmed a "buy" rating and issued a $15.00 price objective on shares of Bioventus in a research note on Monday.March 18, 2025 | marketbeat.comAlphaQuest LLC Increases Stock Holdings in Bioventus Inc. (NYSE:BVS)AlphaQuest LLC raised its position in Bioventus Inc. (NYSE:BVS - Free Report) by 810.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 38,764 shares of the company's stock after acquiring an additionaMarch 14, 2025 | marketbeat.comBioventus (NYSE:BVS) Trading Down 5.9% - Here's WhyBioventus (NYSE:BVS) Stock Price Down 5.9% - Here's What HappenedMarch 13, 2025 | marketbeat.comBioventus Inc. (NASDAQ:BVS) Q4 2024 Earnings Call TranscriptMarch 12, 2025 | msn.comBioventus (NYSE:BVS) Shares Gap Up - Still a Buy?Bioventus (NYSE:BVS) Shares Gap Up - Still a Buy?March 12, 2025 | marketbeat.comBioventus (NYSE:BVS) Updates FY 2025 Earnings GuidanceBioventus (NYSE:BVS) updated its FY 2025 earnings guidance. The company provided EPS guidance of 0.640-0.680 for the period, compared to the consensus estimate of 0.550. The company also issued revenue guidance of $560.0 millionillion-$570.0 millionillion, compared to the consensus estimate of $554.8 millionillion.March 12, 2025 | marketbeat.comBioventus Shares Rise After Improved 4QMarch 12, 2025 | marketwatch.comBioventus reports Q4 non-GAAP EPS 15c, consensus 8cMarch 12, 2025 | markets.businessinsider.comBioventus sees FY25 revenue $560M-$570M, consensus $554.78MMarch 12, 2025 | markets.businessinsider.comBioventus Inc. (BVS) Q4 2024 Earnings Call TranscriptMarch 11, 2025 | seekingalpha.comBioventus Announces Fourth Quarter and Full Year 2024 Financial ResultsMarch 11, 2025 | globenewswire.comCraig-Hallum Reaffirms Their Buy Rating on Bioventus (BVS)March 10, 2025 | markets.businessinsider.comLos Angeles Capital Management LLC Sells 43,144 Shares of Bioventus Inc. (NYSE:BVS)Los Angeles Capital Management LLC trimmed its stake in Bioventus Inc. (NYSE:BVS - Free Report) by 30.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 100,320 shares of the company's stock after selling 43,144March 2, 2025 | marketbeat.comBioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025February 28, 2025 | globenewswire.comBioventus Inc. (NYSE:BVS) SVP Sells $44,632.20 in StockBioventus Inc. (NYSE:BVS - Get Free Report) SVP Anthony D'adamio sold 4,380 shares of the company's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total transaction of $44,632.20. Following the completion of the transaction, the senior vice president now directly owns 118,178 shares in the company, valued at approximately $1,204,233.82. The trade was a 3.57 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.February 21, 2025 | marketbeat.comMark Leonard Singleton Sells 6,498 Shares of Bioventus Inc. (NYSE:BVS) StockBioventus Inc. (NYSE:BVS - Get Free Report) CFO Mark Leonard Singleton sold 6,498 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total value of $66,214.62. Following the completion of the transaction, the chief financial officer now owns 118,817 shares of the company's stock, valued at $1,210,745.23. The trade was a 5.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.February 21, 2025 | marketbeat.comBioventus Inc. (NYSE:BVS) SVP Anthony D'adamio Sells 4,380 SharesFebruary 21, 2025 | insidertrades.comStephens Inc. AR Sells 28,925 Shares of Bioventus Inc. (NYSE:BVS)Stephens Inc. AR decreased its stake in Bioventus Inc. (NYSE:BVS - Free Report) by 51.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 26,775 shares of the company's stock after selling 28,925 shares duriFebruary 17, 2025 | marketbeat.comSpire Wealth Management Buys New Position in Bioventus Inc. (NYSE:BVS)Spire Wealth Management purchased a new position in shares of Bioventus Inc. (NYSE:BVS - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 38,243 shares of the company's stock, valuedFebruary 6, 2025 | marketbeat.comWith 32% ownership, Bioventus Inc. (NASDAQ:BVS) has piqued the interest of institutional investorsJanuary 31, 2025 | finance.yahoo.comJPMorgan Chase & Co. Raises Position in Bioventus Inc. (NYSE:BVS)JPMorgan Chase & Co. lifted its holdings in shares of Bioventus Inc. (NYSE:BVS - Free Report) by 228.3% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 253,740 shares of the company's stock after purchasing an additionalJanuary 20, 2025 | marketbeat.comRobert E. Claypoole Sells 28,786 Shares of Bioventus Inc. (NYSE:BVS) StockBioventus Inc. (NYSE:BVS - Get Free Report) CEO Robert E. Claypoole sold 28,786 shares of the business's stock in a transaction on Monday, January 13th. The stock was sold at an average price of $9.10, for a total value of $261,952.60. Following the sale, the chief executive officer now owns 64,964 shares of the company's stock, valued at approximately $591,172.40. The trade was a 30.71 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.January 14, 2025 | marketbeat.comBioventus to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 7, 2025 | markets.businessinsider.comCraig-Hallum Issues a Buy Rating on Bioventus (BVS)January 7, 2025 | markets.businessinsider.comBioventus: Amply Rewarded For Recent ProgressJanuary 5, 2025 | seekingalpha.comBioventus, Inc.: Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed PartnersJanuary 3, 2025 | finanznachrichten.deBioventus completes divestiture of its Advanced Rehabilitation businessJanuary 3, 2025 | markets.businessinsider.comBioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed PartnersJanuary 2, 2025 | globenewswire.comBioventus Inc. (NYSE:BVS) Shares Purchased by Geode Capital Management LLCGeode Capital Management LLC increased its holdings in shares of Bioventus Inc. (NYSE:BVS - Free Report) by 7.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 940,496 shares of the company's stock aftJanuary 1, 2025 | marketbeat.comFranklin Resources Inc. Takes $1.01 Million Position in Bioventus Inc. (NYSE:BVS)Franklin Resources Inc. purchased a new position in Bioventus Inc. (NYSE:BVS - Free Report) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 80,412 shares of the company's stock, valued at approximately $1,011,000.December 29, 2024 | marketbeat.comState Street Corp Has $8.08 Million Stock Holdings in Bioventus Inc. (NYSE:BVS)State Street Corp grew its holdings in shares of Bioventus Inc. (NYSE:BVS - Free Report) by 38.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 676,501 shares of the company's stock after buying an additional 189December 28, 2024 | marketbeat.comInsider Selling: Bioventus Inc. (NYSE:BVS) SVP Sells 2,535 Shares of StockDecember 27, 2024 | insidertrades.comKatrina J. Church Sells 2,535 Shares of Bioventus Inc. (NYSE:BVS) StockBioventus Inc. (NYSE:BVS - Get Free Report) SVP Katrina J. Church sold 2,535 shares of the company's stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $10.53, for a total transaction of $26,693.55. Following the transaction, the senior vice president now owns 47,264 shares in the company, valued at approximately $497,689.92. This trade represents a 5.09 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.December 26, 2024 | marketbeat.comBioventus Inc. (NYSE:BVS) CFO Sells $113,018.49 in StockBioventus Inc. (NYSE:BVS - Get Free Report) CFO Mark Leonard Singleton sold 10,733 shares of the company's stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $10.53, for a total transaction of $113,018.49. Following the transaction, the chief financial officer now owns 105,162 shares in the company, valued at approximately $1,107,355.86. The trade was a 9.26 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.December 26, 2024 | marketbeat.comShareholder lawsuit ends with $15 million settlementDecember 24, 2024 | bizjournals.comBioventus: Strategic Moves Amidst Financial Challenges Justify Hold RatingDecember 17, 2024 | markets.businessinsider.com Remove Ads Get Bioventus News Delivered to You Automatically Sign up to receive the latest news and ratings for BVS and its competitors with MarketBeat's FREE daily newsletter. Email Address BVS Media Mentions By Week BVS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BVS News Sentiment▼1.120.79▲Average Medical News Sentiment BVS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BVS Articles This Week▼52▲BVS Articles Average Week Remove Ads Get Bioventus News Delivered to You Automatically Sign up to receive the latest news and ratings for BVS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LivaNova News LeMaitre Vascular News Enovis News NovoCure News CONMED News Warby Parker News Cadre News Kestra Medical Technologies News Liquidia News Tandem Diabetes Care News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:BVS) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioventus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioventus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
